RxDoctor Payments Data

Ileana Berman, MD

Psychiatry · Attleboro, MANPI 1245277961

Payments from drug & device makers

$4,439in general payments, 2019–2025

Across 341 payments — averaging $13.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$1K
  • AbbVie$656
  • Johnson & Johnson$542
  • Sunovion Pharmaceuticals Inc.$511
  • Takeda Pharmaceuticals U.S.A., Inc.$416
  • Neurocrine Biosciences, Inc.$299
  • plus $652 from 8 others

What the payments were for

  • Food & beverage$4,426100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,439 in reported general payments places this provider in the 90th percentile of 1,431 psychiatry providers in Massachusetts.

See all psychiatry providers in Massachusetts

Medicare billing

Part B allowed, 2024
$101,560
Medicare patients
210
Services billed
1,270

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole386$1,027,377
Invega SustennaPaliperidone Palmitate128$375,663
Invega TrinzaPaliperidone Palmitate26$222,204
IngrezzaValbenazine Tosylate23$197,350
AristadaAripiprazole Lauroxil64$183,534
TrintellixVortioxetine Hydrobromide252$141,791
Lurasidone Hcl189$84,658
RexultiBrexpiprazole49$78,872
VraylarCariprazine Hcl44$72,075
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl921$52,220
FanaptIloperidone25$26,720
Aripiprazole523$26,467
SuboxoneBuprenorphine Hcl/Naloxone Hcl33$14,635
Quetiapine Fumarate594$10,533
SeroquelQuetiapine Fumarate11$6,496

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$1,364$1,106,249435 claims
Johnson & JohnsonInvega Sustenna, Invega Trinza$542$597,866154 claims
Neurocrine Biosciences, Inc.Ingrezza$299$197,35023 claims
Alkermes, Inc.Aristada$184$183,53464 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$416$141,791252 claims
AbbVieVraylar$656$72,07544 claims
Vanda Pharmaceuticals Inc.Fanapt$108$26,72025 claims
Orexo US, Inc.Zubsolv$74$3,40919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,431 psychiatry providers in Massachusetts.

Other psychiatry in Attleboro

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →